Dr. Xiangrui Meng: “VEGF-TKI + PD-1 Inhibitor + Chemotherapy” as a Potential New Treatment Option for PD-L1-Negative Advanced Gastric Cancer

Dr. Xiangrui Meng: “VEGF-TKI + PD-1 Inhibitor + Chemotherapy” as a Potential New Treatment Option for PD-L1-Negative Advanced Gastric Cancer

In recent years, the emergence and breakthrough progress of multiple targeted and immunotherapy drugs, along with their combination regimens, have brought significant transformation to the systemic treatment of esophageal and gastric cancer. The field has evolved from monotherapy with targeted or immune agents to an era of dual or multi-immunotherapy combinations.
ASCO GI 2025 | Dr. Ying Yuan: BBCAPX Regimen as a Potential Immunotherapy Breakthrough for RAS-Mutant MSS mCRC with Liver Metastases

ASCO GI 2025 | Dr. Ying Yuan: BBCAPX Regimen as a Potential Immunotherapy Breakthrough for RAS-Mutant MSS mCRC with Liver Metastases

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) commenced in San Francisco on January 23, 2025. During the conference, Dr. Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine presented the latest survival data and subgroup analysis from the BBCAPX study. Oncology Frontier had the privilege of discussing the updated findings with Dr. Ying Yuan. This article summarizes the key insights from the study to provide valuable updates for clinicians and researchers.
World’s First! Fatal Cases of Orupuche Fever Confirmed

World’s First! Fatal Cases of Orupuche Fever Confirmed

On the 25th, the Brazilian Ministry of Health announced the confirmation of two fatal cases caused by Orupuche fever. The deceased were two women from the inland region of Bahia State, both under the age of 30 and without any other illnesses. These are the first recorded fatalities due to Orupuche fever worldwide.
For Advanced HR+/HER2- Breast Cancer Patients with Progression after CDK4/6i Treatment, Should We Choose Endocrine Therapy or ADC?

For Advanced HR+/HER2- Breast Cancer Patients with Progression after CDK4/6i Treatment, Should We Choose Endocrine Therapy or ADC?

For advanced HR+/HER2- breast cancer patients with progression after CDK4/6i treatment, would you prefer endocrine therapy or ADC (antibody-drug conjugate) treatment? In the "In-depth Debate" session of the 2024 Breast Cancer Summer Forum - Northern Salon, Dr. Xu Liang from Peking University Cancer Hospital and Dr. Nanlin Li from Xijing Hospital of Air Force Medical University expressed their views. Dr. Xu Liang favored endocrine therapy, while Dr. Nanlin Li preferred ADC treatment. After the forum, Oncology Frontier invited both experts to elaborate on their perspectives.
In-Depth Analysis丨Dr. Wei Li & Dr. Shaohua Zhang: First-Line Treatment Options for Patients with Recurrent Metastatic Triple-Negative Breast Cancer

In-Depth Analysis丨Dr. Wei Li & Dr. Shaohua Zhang: First-Line Treatment Options for Patients with Recurrent Metastatic Triple-Negative Breast Cancer

For patients with recurrent metastatic triple-negative breast cancer (TNBC), would you choose "chemotherapy + immunotherapy" or "ADC" for treatment? At the 2024 Breast Cancer Summer Forum·Northern Salon "In-Depth Analysis" session, Dr. Wei Li from Jiangsu Provincial People's Hospital and Dr. Shaohua Zhang from the Chinese PLA General Hospital presented their respective viewpoints. Dr. Wei Li expressed a preference for "chemotherapy + immunotherapy," while Dr. Shaohua Zhang opted for "ADC." Following the session, Oncology Frontier invited the two experts to elaborate on their perspectives.
In-Depth Analysis丨Dr. Qiang Zhang & Dr. Li Wang: Neoadjuvant Immunotherapy Choices for Triple-Negative Breast Cancer

In-Depth Analysis丨Dr. Qiang Zhang & Dr. Li Wang: Neoadjuvant Immunotherapy Choices for Triple-Negative Breast Cancer

For neoadjuvant immunotherapy in triple-negative breast cancer (TNBC), do you prefer the "TP-AC" or "TP" regimen? At the 2024 Breast Cancer Summer Forum · Northern Salon's "Raising Questions and Seeking Answers" session, Dr. Qiang Zhang from Liaoning Cancer Hospital and Dr. Li Wang from Xingtai People's Hospital presented their viewpoints. Dr. Qiang Zhang favors the TP-AC regimen, while Dr. Li Wang opts for the TP regimen. After the session, Oncology Frontier invited both experts to elaborate on their perspectives.